Knight Therapeutics Stock Performance
| KHTRF Stock | USD 3.73 0.02 0.53% |
The company secures a Beta (Market Risk) of -0.1, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Knight Therapeutics are expected to decrease at a much lower rate. During the bear market, Knight Therapeutics is likely to outperform the market. At this point, Knight Therapeutics has a negative expected return of -0.3%. Please make sure to verify Knight Therapeutics' maximum drawdown, as well as the relationship between the rate of daily change and relative strength index , to decide if Knight Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Knight Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 229.6 M | |
| Total Cashflows From Investing Activities | -105.3 M |
Knight |
Knight Therapeutics Relative Risk vs. Return Landscape
If you would invest 455.00 in Knight Therapeutics on September 16, 2024 and sell it today you would lose (82.00) from holding Knight Therapeutics or give up 18.02% of portfolio value over 90 days. Knight Therapeutics is currently producing negative expected returns and takes up 1.2665% volatility of returns over 90 trading days. Put another way, 11% of traded pink sheets are less volatile than Knight, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Knight Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Knight Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Knight Therapeutics, and traders can use it to determine the average amount a Knight Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2346
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KHTRF |
Estimated Market Risk
| 1.27 actual daily | 11 89% of assets are more volatile |
Expected Return
| -0.3 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.23 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Knight Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Knight Therapeutics by adding Knight Therapeutics to a well-diversified portfolio.
Knight Therapeutics Fundamentals Growth
Knight Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Knight Therapeutics, and Knight Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Knight Pink Sheet performance.
| Return On Equity | -0.0266 | |||
| Return On Asset | -0.0133 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (0.08) % | |||
| Current Valuation | 354.32 M | |||
| Shares Outstanding | 113.96 M | |||
| Price To Earning | 15.30 X | |||
| Price To Book | 0.69 X | |||
| Price To Sales | 1.67 X | |||
| Revenue | 243.48 M | |||
| EBITDA | 58.22 M | |||
| Cash And Equivalents | 147.08 M | |||
| Cash Per Share | 1.28 X | |||
| Total Debt | 9.27 M | |||
| Debt To Equity | 0.05 % | |||
| Book Value Per Share | 7.50 X | |||
| Cash Flow From Operations | 44.62 M | |||
| Earnings Per Share | (0.04) X | |||
| Total Asset | 991.89 M | |||
About Knight Therapeutics Performance
By analyzing Knight Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Knight Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Knight Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Knight Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada. Knight Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 660 people.Things to note about Knight Therapeutics performance evaluation
Checking the ongoing alerts about Knight Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Knight Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Knight Therapeutics generated a negative expected return over the last 90 days | |
| About 31.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Knight Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Knight Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Knight Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Knight Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Knight Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Knight Therapeutics' pink sheet. These opinions can provide insight into Knight Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Knight Pink Sheet analysis
When running Knight Therapeutics' price analysis, check to measure Knight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Knight Therapeutics is operating at the current time. Most of Knight Therapeutics' value examination focuses on studying past and present price action to predict the probability of Knight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Knight Therapeutics' price. Additionally, you may evaluate how the addition of Knight Therapeutics to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |